{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:16:46Z","timestamp":1788383806172,"version":"build-2803163510"},"reference-count":57,"publisher":"Portland Press Ltd.","issue":"2","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The pathogenesis of reactive arthritis (ReA) has not been fully elucidated. In recent years, many researchers have confirmed that multiple cytokines are involved in the occurrence and development of ReA. Although ReA is self-limiting, it is still incurable for some patients who have no or a weak response to traditional drugs, such as non-steroidal anti-inflammatory agents, glucocorticoids and immunosuppressive agents. This is called refractory reactive arthritis. Currently, there is insufficient evidences for the treatment of refractory ReA with biological agents, though biological agents against cytokines have been developed over the past few years. This review summarizes the current development of clinical treatments of ReA with biological agents, which provides future investigations on refractory ReA with more evidence and references.<\/jats:p>","DOI":"10.1042\/bsr20191927","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T11:47:07Z","timestamp":1581335227000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Treatment of reactive arthritis with biological agents: a review"],"prefix":"10.1042","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-1837","authenticated-orcid":false,"given":"Huiqiong","family":"Zeng","sequence":"first","affiliation":[{"name":"Shenzhen Futian hospital for Rheumatic diseases, Futian District, #22 Nonglin Road, Shenzhen 518040, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiwei","family":"Luo","sequence":"additional","affiliation":[{"name":"Shenzhen Futian hospital for Rheumatic diseases, Futian District, #22 Nonglin Road, Shenzhen 518040, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shenzhen Futian hospital for Rheumatic diseases, Futian District, #22 Nonglin Road, Shenzhen 518040, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, the Eighth Affiliated Hospital of Sun Yat-sen University, Futian District, #3025Shennanzhong Road, Shenzhen 518040, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2480-6004","authenticated-orcid":false,"given":"Zhizhong","family":"Ye","sequence":"additional","affiliation":[{"name":"Shenzhen Futian hospital for Rheumatic diseases, Futian District, #22 Nonglin Road, Shenzhen 518040, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"2021111620022430900_B1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3109\/07853890.2011.606830","article-title":"Chlamydia and chronic arthritis","volume":"44","author":"Carter","year":"2012","journal-title":"Ann. Med."},{"key":"2021111620022430900_B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.rdc.2009.03.010","article-title":"Reactive arthritis: clinical aspects and medical management","volume":"35","author":"Carter","year":"2009","journal-title":"Rheum. Disease Clin."},{"key":"2021111620022430900_B3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/1756-185X.12920","article-title":"Microbe-triggered arthropathies: reactive arthritis and beyond","volume":"19","author":"Gupta","year":"2016","journal-title":"Int. J. Rheum. Diseases"},{"key":"2021111620022430900_B4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.40359","article-title":"Gut microbiota perturbations in reactive arthritis and postinfectious spondyloarthritis","volume":"70","author":"Manasson","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"2021111620022430900_B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.reuma.2016.08.001","article-title":"Evolution over thirty years of the profile of inpatients with reactive arthritis in a tertiary rheumatology unit","volume":"14","author":"Brinster","year":"2018","journal-title":"Reumatol. Cl\u00edn."},{"key":"2021111620022430900_B6","first-page":"827","article-title":"Reactive arthritis: defined etiologies, emerging pathophysiology, and unresolved treatment","volume":"20","author":"Carter","year":"2006","journal-title":"Infect. Disease Clin."},{"key":"2021111620022430900_B7","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/rheumatology\/keh323","article-title":"Different cytokine profiles in patients with chronic and acute reactive arthritis","volume":"43","author":"Butrimiene","year":"2004","journal-title":"Rheumatology"},{"key":"2021111620022430900_B8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/RHU.0b013e31824e9151","article-title":"Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab","volume":"18","author":"Gaylis","year":"2012","journal-title":"J. Clin. Rheumatol."},{"key":"2021111620022430900_B9","doi-asserted-by":"crossref","first-page":"R150","DOI":"10.1186\/ar3886","article-title":"Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis","volume":"14","author":"Inman","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"2021111620022430900_B10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/1529-0131(199901)42:1<84::AID-ANR11>3.0.CO;2-C","article-title":"Salmonella-triggered reactive arthritis: use of polymerase chain reaction, immunocytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid","volume":"42","author":"Nikkari","year":"1999","journal-title":"Arthritis Rheum."},{"key":"2021111620022430900_B11","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3899\/jrheum.130136","article-title":"Attack rate of Chlamydia-induced reactive arthritis and effect of the CCR5-Delta-32 mutation: a prospective analysis","volume":"40","author":"Carter","year":"2013","journal-title":"J. Rheumatol."},{"key":"2021111620022430900_B12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2217\/ijr.12.65","article-title":"The molecular basis for disease phenotype in chronic Chlamydia-induced arthritis","volume":"7","author":"Carter","year":"2012","journal-title":"Int. J. Clin. Rheumatol."},{"key":"2021111620022430900_B13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/1744666X.2017.1233816","article-title":"Recent advances and future directions in understanding and treating Chlamydia-induced reactive arthritis","volume":"13","author":"Carter","year":"2017","journal-title":"Exp. Rev. Clin. Immunol."},{"key":"2021111620022430900_B14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/art.39041","article-title":"High Chlamydia burden promotes tumor necrosis factor-dependent reactive arthritis in SKG mice","volume":"67","author":"Baillet","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"2021111620022430900_B15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10067-010-1646-5","article-title":"Th-17 associated cytokines in patients with reactive arthritis\/undifferentiated spondyloarthropathy","volume":"30","author":"Singh","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"2021111620022430900_B16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.21643","article-title":"Early cytokine profiles in the joint define pathogen clearance and severity of arthritis in Chlamydia-induced arthritis in rats","volume":"54","author":"Inman","year":"2006","journal-title":"Arthritis Rheum."},{"key":"2021111620022430900_B17","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.4049\/jimmunol.162.9.5045","article-title":"Cutting edge: HLA-B27 can form a novel \u03b22-microglobulin-free heavy chain homodimer structure","volume":"162","author":"Allen","year":"1999","journal-title":"J. Immunol."},{"key":"2021111620022430900_B18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s11926-996-0012-8","article-title":"Pathogenesis of reactive arthritis","volume":"3","author":"Sieper","year":"2001","journal-title":"Curr. Rheumatol. Rep."},{"key":"2021111620022430900_B19","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3899\/jrheum.080395","article-title":"Influence of HLA-B* 5703 and HLA-B* 1403 on susceptibility to spondyloarthropathies in the Zambian population","volume":"35","author":"Diaz-Pena","year":"2008","journal-title":"J. Rheumatol."},{"key":"2021111620022430900_B20","first-page":"47","article-title":"The modulation of chlamydial replication by HLA-B27 depends on the cytoplasmic domain of HLA-B27","volume":"19","author":"Kuipers","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"2021111620022430900_B21","doi-asserted-by":"publisher","first-page":"e34093","DOI":"10.1371\/journal.pone.0034093","article-title":"HLA-B27 modulates intracellular growth of Salmonella pathogenicity island 2 mutants and production of cytokines in infected monocytic U937 cells","volume":"7","author":"Ge","year":"2012","journal-title":"PLoS One"},{"key":"2021111620022430900_B22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11926-004-0055-7","article-title":"Disease mechanisms in reactive arthritis","volume":"6","author":"Sieper","year":"2004","journal-title":"Curr. Rheumatol. Rep."},{"key":"2021111620022430900_B23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.molimm.2013.07.013","article-title":"HLA-B27 misfolding and ankylosing spondylitis","volume":"57","author":"Colbert","year":"2014","journal-title":"Mol. Immunol."},{"key":"2021111620022430900_B24","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.1780401010","article-title":"Crucial role of interleukin-10\/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis","volume":"40","author":"Yin","year":"1997","journal-title":"Arthritis Rheum."},{"key":"2021111620022430900_B25","first-page":"S130","article-title":"TNF involvement and anti-TNF therapy of reactive and unclassified arthritis","volume":"20","author":"Meador","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"2021111620022430900_B26","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fcimb.2017.00398","article-title":"Activation of iNKT cells prevents Salmonella enterocolitis and Salmonella-induced reactive arthritis by downregulating IL-17-producing \u03b3\u03b4T cells","volume":"7","author":"Noto Llana","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"2021111620022430900_B27","doi-asserted-by":"publisher","first-page":"8562","DOI":"10.1073\/pnas.91.18.8562","article-title":"Divergent T-cell cytokine patterns in inflammatory arthritis","volume":"91","author":"Simon","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2021111620022430900_B28","first-page":"2285","article-title":"Th1\/Th17 cytokine profiles in patients with reactive arthritis\/undifferentiated spondyloarthropathy","volume":"34","author":"Singh","year":"2007","journal-title":"J. Rheumatol."},{"key":"2021111620022430900_B29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2362.1991.tb01398.x","article-title":"Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients","volume":"21","author":"Holt","year":"1991","journal-title":"Eur. J. Clin. Invest."},{"key":"2021111620022430900_B30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/cei.12799","article-title":"Recombinant Salmonella typhimurium outer membrane protein A is recognized by synovial fluid CD8 cells and stimulates synovial fluid mononuclear cells to produce interleukin (IL)-17\/IL-23 in patients with reactive arthritis and undifferentiated spondyloarthropathy","volume":"185","author":"Chaurasia","year":"2016","journal-title":"Clin. & Exp. Immunol."},{"key":"2021111620022430900_B31","doi-asserted-by":"crossref","first-page":"e82588","DOI":"10.1371\/journal.pone.0082588","article-title":"Consumption of Lactobacillus casei fermented milk prevents Salmonella reactive arthritis by modulating IL-23\/IL-17 expression","volume":"8","author":"Llana","year":"2013","journal-title":"PLoS One"},{"key":"2021111620022430900_B32","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1128\/IAI.71.4.1804-1812.2003","article-title":"Attenuated Yersinia enterocolitica mutant strains exhibit differential virulence in cytokine-deficient mice: implications for the development of novel live carrier vaccines","volume":"71","author":"Di Genaro","year":"2003","journal-title":"Infect. Immun."},{"key":"2021111620022430900_B33","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/infdis\/172.5.1290","article-title":"Pathogen antigen-and superantigen-reactive synovial fluid T-cells in reactive arthritis","volume":"172","author":"Lahesmaa","year":"1995","journal-title":"J. Infect. Dis."},{"key":"2021111620022430900_B34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/icb.2012.65","article-title":"TNFRp55 controls regulatory T cell responses in Yersinia-induced reactive arthritis","volume":"91","author":"Cargnelutti","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"2021111620022430900_B35","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s11926-012-0280-4","article-title":"Reactive arthritis: developments and challenges in diagnosis and treatment","volume":"14","author":"Morris","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"2021111620022430900_B36","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3899\/jrheum.121192","article-title":"Antibiotics for treatment of reactive arthritis: a systematic review and meta-analysis","volume":"40","author":"Barber","year":"2013","journal-title":"J. Rheumatol."},{"key":"2021111620022430900_B37","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/art.27394","article-title":"Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial","volume":"62","author":"Carter","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2021111620022430900_B38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/RHU.0b013e3181d06f70","article-title":"Prolonged remission of chronic reactive arthritis treated with three infusions of infliximab","volume":"16","author":"Wechalekar","year":"2010","journal-title":"J. Clin. Rheumatol."},{"key":"2021111620022430900_B39","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21323","article-title":"Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial","volume":"53","author":"Flagg","year":"2005","journal-title":"Arthritis Care Res."},{"key":"2021111620022430900_B40","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/art.30272","article-title":"Safety and efficacy of anti-tumor necrosis factor \u03b1 therapy in ten patients with recent-onset refractory reactive arthritis","volume":"63","author":"Meyer","year":"2011","journal-title":"Arthritis Rheum."},{"key":"2021111620022430900_B41","first-page":"265","article-title":"Reactive arthritis","volume":"31","author":"Schmitt","year":"2017","journal-title":"Infect. Disease Clin."},{"key":"2021111620022430900_B42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrrheum.2016.42","article-title":"New evidence on the management of spondyloarthritis","volume":"12","author":"Sieper","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"2021111620022430900_B43","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.annder.2017.08.004","article-title":"A case of reactive arthritis (oculo-urethro-synovial syndrome) treated with infliximab","volume":"144","author":"Ahogo","year":"2017","journal-title":"Ann. Dermatol. Venereol."},{"key":"2021111620022430900_B44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/03009740310000157","article-title":"Treatment of reactive arthritis with infliximab","volume":"32","author":"Kaipiainen-Sepp\u00e4nen","year":"2003","journal-title":"Scand. J. Rheumatol."},{"key":"2021111620022430900_B45","first-page":"407","article-title":"Infliximab in the treatment of an HIV positive patient with Reiter\u2019s syndrome","volume":"30","author":"Gaylis","year":"2003","journal-title":"J. Rheumatol."},{"key":"2021111620022430900_B46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10067-007-0692-0","article-title":"Successful use of infliximab in the treatment of Reiter\u2019s syndrome: a case report and discussion","volume":"27","author":"Gill","year":"2008","journal-title":"Clin. Rheumatol."},{"key":"2021111620022430900_B47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00296-009-0965-9","article-title":"Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection","volume":"30","author":"Schafranski","year":"2010","journal-title":"Rheumatol. Int."},{"key":"2021111620022430900_B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00296-011-2000-1","article-title":"Successful use of etanercept for the treatment of Reiter\u2019s syndrome: a case report and review of the literature","volume":"32","author":"Edrees","year":"2012","journal-title":"Rheumatol. Int."},{"key":"2021111620022430900_B49","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/RHU.0b013e3180690c1f","article-title":"Use of adalimumab in poststreptococcal reactive arthritis","volume":"13","author":"S\u00e1nchez-Cano","year":"2007","journal-title":"J. Clin. Rheumatol."},{"key":"2021111620022430900_B50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/BF00290261","article-title":"Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus","volume":"12","author":"Mets\u00e4rinne","year":"1992","journal-title":"Rheumatol. Int."},{"key":"2021111620022430900_B51","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/art.10177","article-title":"Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis","volume":"46","author":"Straub","year":"2002","journal-title":"Arthritis Rheum."},{"key":"2021111620022430900_B52","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/art.24899","article-title":"Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"61","author":"Tanaka","year":"2009","journal-title":"Arthritis Care Res."},{"key":"2021111620022430900_B53","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10067-018-4022-5","article-title":"Reactive arthritis: update 2018","volume":"37","author":"Garc\u00eda-Kutzbach","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"2021111620022430900_B54","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/1346-8138.14145","article-title":"Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: a single-center experience","volume":"45","author":"Momose","year":"2018","journal-title":"J. Dermatol."},{"key":"2021111620022430900_B55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"2021111620022430900_B56","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40070","article-title":"Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study","volume":"69","author":"Blanco","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"2021111620022430900_B57","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/art.40581","article-title":"Interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses","volume":"70","author":"Van Mens","year":"2018","journal-title":"Arthritis Rheumatol."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20191927\/868173\/bsr-2019-1927.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20191927\/868173\/bsr-2019-1927.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T15:47:19Z","timestamp":1695743239000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/40\/2\/BSR20191927\/222065\/Treatment-of-reactive-arthritis-with-biological"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,28]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20191927","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2020,2]]},"article-number":"BSR20191927"}}